arrow
A

Aggelos Banos

department of rheumatology
H指数:18
被引数:1,380

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study

系统性红斑狼疮患者出现肾小球血尿时与临床显著性肾炎相关的因素:一项横断面研究

2026-08-070
OAAI
Disease-related and psychosocial factors associated with difficult-to-manage and treatment-refractory axial spondyloarthritis: insights from the Greek AxSpA Registry

与难治性和治疗抵抗性轴性脊柱关节炎相关的疾病相关和心理社会因素:来自希腊AxSpA登记研究的见解

2026-07-080
PRE
Clinical and Serological Characteristics of Idiopathic Inflammatory Myopathies According to the Presence of Interstitial Lung Disease and Initial Evaluating Medical Specialty: A Single-Center Experience

根据间质性肺疾病存在与否及初始评估专科的不同,特发性炎性肌病的临床和血清学特征:一项单中心研究

2026-06-080
OA
Peripheral blood transcriptomic analysis of patients with rheumatoid arthritis associated interstitial lung disease reveals: distinct molecular signature with evidence of humoral and myeloid immunity

类风湿关节炎相关间质性肺病患者的外周血转录组分析揭示:具有体液免疫和髓系免疫证据的特异分子特征

2026-05-060
OAAI
The sex-biased chromatin modifier SMC1A promotes autoimmunity by shaping inflammatory pathways in patients with SLE

性别偏倚的染色质修饰因子SMC1A通过塑造炎症通路促进系统性红斑狼疮(SLE)患者的自身免疫。

2025-11-240
OAAI
Increased interferon I signaling, DNA damage response and evidence of T-cell exhaustion in a patient with combined interferonopathy (Aicardi-Goutières Syndrome, AGS) and cohesinopathy (Cornelia de Lange Syndrome, CdLS)

I型干扰素信号增强、DNA损伤应答以及联合干扰素病(Aicardi-Goutières综合征,AGS)和粘连蛋白病(Cornelia de Lange综合征,CdLS)患者中T细胞耗竭的证据

2025-01-270
OA
The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease

SYSCID图谱: 类风湿关节炎,系统性红斑狼疮和炎症性肠病分子机制的图形和计算资源

2023-11-010
OAAI
Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways
2020-05-1429
OAAI
An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion
2019-12-1699
OAAI